Dear friends,
Thank you for your support of FA research over the past year. Together, we reached some important milestones on the journey to treatments and cures for FA. Some of those achievements included:
As you can see from the updates below, 2022 is also off to a busy and impactful start. Thank you for all you've done and continue to do to make this progess possible for all families living with FA.
Sincerely,
Jen
Jennifer Farmer,
FARA Chief Executive Officer
Thank you for your support of FA research over the past year. Together, we reached some important milestones on the journey to treatments and cures for FA. Some of those achievements included:
- Funding over $7.5M in research, including FARA directed projects like a working group on mechanisms of gene silencing, new animal model development, a potency assay to support drug development, and projects on frataxin function
- Leading a community petition with over 70,000 signatures requesting FDA and Reata advance the New Drug Application for Omaveloxolone in FA
- Completing enrollment of Phase 3 trial for PTC-743, MOVE-FA study, with over 140 FAers globally
- Opening a new clinical research site for the Natural History Study in New Delhi, India
As you can see from the updates below, 2022 is also off to a busy and impactful start. Thank you for all you've done and continue to do to make this progess possible for all families living with FA.
Sincerely,
Jen
Jennifer Farmer,
FARA Chief Executive Officer
Our February Monthly Update also provides information on the following topics:
- Pharma News
- The CCRN in FA adds a new site - St. Jude Children's Research Hospital
- FARA Funded Research
- Upcoming In-Person Events
- rideATAXIA
- Rare Disease Day - February 28
- Support FA Research Year-Round Through The Pathway, FARA’s Monthly Giving Program
- Open & Enrolling Studies
More...
